What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Disease
- Surgery
His main research concerns Internal medicine, Scleroderma, Connective tissue disease, Pathology and Surgery.
His Internal medicine research incorporates elements of Gastroenterology and Physical therapy.
His Physical therapy research includes themes of Clinical trial, Epidemiology, MEDLINE, Rheumatism and Disease.
His work carried out in the field of Connective tissue disease brings together such families of science as Systemic disease, Autoantibody and Interstitial lung disease.
His biological study spans a wide range of topics, including Endothelial stem cell, Extracellular matrix, Angiogenesis and Growth factor.
His Surgery study combines topics from a wide range of disciplines, such as Systemic scleroderma and Cohort.
His most cited work include:
- 2013 classification criteria for systemic sclerosis: An american college of rheumatology/European league against rheumatism collaborative initiative (1669 citations)
- American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials (993 citations)
- 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative (583 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Internal medicine, Pathology, Scleroderma, Immunology and Rheumatology.
Cohort is closely connected to Surgery in his research, which is encompassed under the umbrella topic of Internal medicine.
His Pathology research is multidisciplinary, incorporating perspectives in Extracellular matrix and Angiogenesis.
The concepts of his Scleroderma study are interwoven with issues in Systemic disease and Disease.
Rheumatology is closely attributed to Physical therapy in his research.
His Physical therapy research includes elements of Clinical trial, Quality of life and MEDLINE.
He most often published in these fields:
- Internal medicine (43.53%)
- Pathology (19.35%)
- Scleroderma (16.20%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (43.53%)
- Scleroderma (16.20%)
- Disease (12.45%)
In recent papers he was focusing on the following fields of study:
Marco Matucci-Cerinic mostly deals with Internal medicine, Scleroderma, Disease, Interstitial lung disease and Rheumatology.
Marco Matucci-Cerinic frequently studies issues relating to Cardiology and Internal medicine.
Marco Matucci-Cerinic has researched Scleroderma in several fields, including Fibrosis, Severity of illness and Epidemiology.
In his study, Systematic review is strongly linked to Clinical trial, which falls under the umbrella field of Severity of illness.
In his work, MEDLINE is strongly intertwined with Intensive care medicine, which is a subfield of Disease.
His studies in Interstitial lung disease integrate themes in fields like Gastroenterology and Pulmonary function testing.
Between 2017 and 2021, his most popular works were:
- COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs (134 citations)
- Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator‐Initiated, Multicenter, Double‐Blind, Randomized, Placebo‐Controlled Trial (66 citations)
- Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study (61 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Disease
- Surgery
Marco Matucci-Cerinic mainly focuses on Internal medicine, Scleroderma, Interstitial lung disease, Disease and Intensive care medicine.
His study in Rheumatology, Severity of illness, Cohort, Randomized controlled trial and Prospective cohort study falls within the category of Internal medicine.
His Severity of illness study integrates concerns from other disciplines, such as Autoantibody, Physical therapy and Clinical trial.
Marco Matucci-Cerinic interconnects Fibrosis, Phenotype, Pathological and Abatacept in the investigation of issues within Scleroderma.
The various areas that Marco Matucci-Cerinic examines in his Interstitial lung disease study include Azathioprine, Pulmonary function testing and Arthritis.
Marco Matucci-Cerinic combines subjects such as Inflammation, Immune system and Drug with his study of Disease.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
